Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-8958 Phase 3 study
jRCT2080223342Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Influenza A infection and influenza B comparing Laninamivir (CS-8958) 160 mg with Placebo (2 arms). Primary endpoint: Clinical efficacy of laninamivir (CS-8958) 160 mg nebulizer inhaler in influenza A or B infection. Started Oct 2016; status: completed.
02
Drugs
laninamivir
03
Conditions
Influenza A infectioninfluenza B
Beyond the preview
Go deeper on jRCT2080223342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223342.